PURE Bioscience  

(Public, OTCMKTS:PURE)   Watch this stock  
Find more results for NASDAQ:PURE
-0.04 (-3.39%)
Oct 21 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 1.11 - 1.19
52 week 0.94 - 1.70
Open 1.18
Vol / Avg. 46,937.00/80,056.00
Mkt cap 33.03M
P/E     -
Div/yield     -
EPS -0.53
Shares 28.97M
Beta 0.81
Inst. own 3%
Sep 10, 2014
Pure Biosciences Inc at Rodman & Renshaw Global Investment Conference

Key stats and ratios

Q2 (Apr '14) 2013
Net profit margin -785.06% -935.49%
Operating margin -836.78% -895.00%
EBITD margin - -789.88%
Return on average assets -337.93% -235.31%
Return on average equity -752.27% -
Employees 13 -
CDP Score - -


EL CAJON, CA 92020
United States - Map
+1-619-5968600 (Phone)
+1-619-5968690 (Fax)

Website links


Pure Bioscience, Inc. (PURE) is focused on the discovery, development and commercialization of bioscience products. PURE�s technology platform is based on stabilized ionic silver, and its initial products contain silver dihydrogen citrate (SDC).The Company manufactures and sells SDC-based disinfecting and sanitizing products. PURE also manufactures and sells various SDC-based formulations to manufacturers for use as a raw material in the production of personal care and other products. The Company�s products include PURE Complete System, which includes PURE Hard Surface, PURE Multi-Purpose Cleaner Concentrate and PURE Floor Cleaner Concentrate; Axen 30; Axenohl, and Silverion.

Officers and directors

David Pfanzelter Independent Chairman of the Board
Age: 59
Henry R. Lambert Chief Executive Officer, Director
Age: 62
Peter C. Wulff Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Age: 54
Gary D. Cohee Director
Age: 67
William Otis Independent Director
Age: 57
David M. Theno Jr. Ph.D. Independent Director
Age: 62